Fusion Pharmaceuticals Inc.

NASDAQ:FUSN

21.55 (USD) • At close June 3, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 033.6362.0060.0340.0280.140.1660.570.5850.5940.3250.521000000000
Cost of Revenue 0.3610.3611.0440.93115.87717.60716.55112.0760000000000000
Gross Profit -0.36133.2750.962-0.897-15.849-17.467-16.385-11.5060.5850.5940.3250.521000000000
Gross Profit Ratio 00.9890.48-26.382-566.036-124.764-98.705-20.1861111000000000
Reseach & Development Expenses 20.95120.28614.58518.99415.87717.60716.55112.07612.66111.81112.68421.14610.7164.964.5293.3254.3773.4162.2382.1372.841
General & Administrative Expenses 14.5487.6286.817.7539.0066.957.427.7818.4496.3367.1566.6426.9646.6395.793.9884.3272.7241.9221.7711.171
Selling & Marketing Expenses 000000000000000000000
SG&A 14.5487.6286.817.7539.0066.957.427.7818.4496.3367.1566.6426.9646.6395.793.9884.3272.7241.9221.7711.171
Other Expenses 0.2970.4360.3910.08-0.145-0.68-1.159-0.4140.4780.0630.0270.3310.0480.8590.02-31.279-1.315-2.2533.4560.2780.049
Operating Expenses 35.49927.91421.39526.74724.88324.55723.97119.85721.1118.14719.8427.78817.6811.73810.2787.2618.6586.0964.1163.8643.968
Operating Income -35.86-28.275-19.389-26.713-24.855-24.417-23.805-19.287-20.525-17.553-19.515-27.267-17.68-11.599-10.319-7.313-8.704-6.14-4.16-3.908-4.012
Operating Income Ratio 0-0.841-9.666-785.676-887.679-174.407-143.404-33.837-35.085-29.551-60.046-52.336000000000
Total Other Income Expenses Net 1.9531.3921.8841.2930.553-0.54-0.969-0.4670.5610.1440.1340.4280.1440.7980.141-37.27-1.456-2.0283.7470.470.093
Income Before Tax -33.907-26.883-17.505-25.42-24.302-24.957-24.774-19.754-19.964-17.409-19.381-26.839-17.536-10.801-10.178-44.583-10.16-8.168-0.413-3.438-3.919
Income Before Tax Ratio 0-0.799-8.726-747.647-867.929-178.264-149.241-34.656-34.126-29.308-59.634-51.514000000000
Income Tax Expense -0.2371.296-0.253-0.245-0.011-0.34-0.761-0.681-0.055-0.1730.0480.014-0.0072.584-0.1850.150.0620.0380.1810.0180.014
Net Income -33.67-28.179-17.252-25.175-24.291-24.617-24.013-19.073-19.909-17.236-19.429-26.853-17.529-13.385-9.993-44.733-10.222-8.206-0.594-3.456-3.933
Net Income Ratio 0-0.838-8.6-740.441-867.536-175.836-144.657-33.461-34.032-29.017-59.782-51.541000000000
EPS -0.4-0.39-0.25-0.38-0.45-0.55-0.55-0.44-0.46-0.4-0.45-0.63-0.42-0.32-0.24-18.91-0.25-0.39-0.028-0.16-0.18
EPS Diluted -0.4-0.39-0.25-0.38-0.45-0.55-0.55-0.44-0.46-0.4-0.45-0.63-0.42-0.32-0.24-18.91-0.25-0.39-0.028-0.16-0.18
EBITDA -35.499-27.914-19.389-23.801-23.079-23.788-23.563-19.071-20.322-17.553-19.33-27.113-17.569-11.738-10.175-1.098-8.152-6.019-4.037-3.793-3.905
EBITDA Ratio 0-0.83-9.666-700.029-824.25-169.914-141.946-33.458-34.738-29.551-59.477-52.04000000000